Publication: Successful treatment of factor x deficiency in a patient with lymphoplasmacytic lymphoma with bendamustine plus rituximab regimen: A case report and literature review
Issued Date
2021-01-01
Resource Type
ISSN
11792736
Other identifier(s)
2-s2.0-85119686059
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Blood Medicine. Vol.12, (2021), 875-881
Suggested Citation
Tarinee Rungjirajittranon, Yingyong Chinthammitr, Chattree Hantaweepant Successful treatment of factor x deficiency in a patient with lymphoplasmacytic lymphoma with bendamustine plus rituximab regimen: A case report and literature review. Journal of Blood Medicine. Vol.12, (2021), 875-881. doi:10.2147/JBM.S336635 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78562
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Successful treatment of factor x deficiency in a patient with lymphoplasmacytic lymphoma with bendamustine plus rituximab regimen: A case report and literature review
Other Contributor(s)
Abstract
Background: Acquired factor X deficiency is an uncommon condition, and affected indi-viduals have severe and spontaneous bleeding. The associated conditions include malig-nancy, infection, burn, and inflammatory bowel disease. Many previous studies reported association between lymphoproliferative disease and factor X disappearance. Amyloid deposition causing factor X absorption was the most common mechanism. Here, we report a case of stage IV lymphoplasmacytic lymphoma (LPL) with factor X deficiency who was successfully treated with bendamustine plus rituximab (BR) regimen. Case Presentation: A 52-year-old Thai woman presented with heavy menorrhea, hoarseness, and widespread ecchymosis at her extremities. On physical examination, the patient had bilateral periorbital purpura and vocal cord hematoma. Coagulation testing showed prolonged prothrom-bin time (PT) and prolonged activated thromboplastin time (aPTT); however, after mixing with 1:1 normal pooled plasma, PT and aPTT were both corrected to normal levels. Factor assays demonstrated markedly decreased factor X levels, but no presence of factor X inhibitor. Bone marrow examination revealed numerous abnormal lymphoplasmacytoid lymphocytes with kappa light chain expression. Serum free light chain assay also showed kappa light chain restriction [kappa 716.16 mg/L, lambda 16.96 mg/L, ratio 42.23 (0.26–1.65)]. The patient was diagnosed as lymphoplasmacytic lymphoma with factor X deficiency. She received chemother-apy with 6 cycles of bendamustine plus rituximab (BR) regimen. The patient responded favorably to treatment, she remains in lymphoma remission at one year after diagnosis, and her factor X level was more than 20%. Conclusion: We performed a literature review to identify previous case reports about lymphoma-associated factor X deficiency or inhibitor to determine a possible explanation in our patient. It is important to emphasize that when patients present with acquired factor deficiency, including factor X, lymphoproliferative disease is commonly one of the under-lying conditions. Furthermore, the recovery of coagulation factor deficiency is possible if successful remission of lymphoma can be achieved.